Merus (NASDAQ:MRUS) Shares Bought by Fmr LLC

Fmr LLC lifted its stake in shares of Merus (NASDAQ:MRUS) by 10.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,873,926 shares of the biotechnology company’s stock after acquiring an additional 648,994 shares during the period. Fmr LLC owned 0.10% of Merus worth $343,421,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. nVerses Capital LLC lifted its holdings in Merus by 750.0% in the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 1,500 shares in the last quarter. US Bancorp DE acquired a new position in shares of Merus in the third quarter valued at approximately $103,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Merus by 24.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 489 shares during the last quarter. Farallon Capital Management LLC purchased a new position in shares of Merus during the second quarter valued at approximately $237,000. Finally, ProShare Advisors LLC acquired a new stake in Merus during the second quarter worth approximately $242,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on MRUS shares. HC Wainwright reiterated a “buy” rating and issued a $85.00 price target on shares of Merus in a report on Friday, November 1st. The Goldman Sachs Group began coverage on Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price for the company. UBS Group initiated coverage on Merus in a research report on Thursday, October 24th. They set a “buy” rating and a $72.00 target price on the stock. Guggenheim lifted their price target on Merus from $93.00 to $111.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $85.00 price objective on shares of Merus in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Merus presently has an average rating of “Buy” and a consensus price target of $85.45.

Merus Stock Down 0.3 %

Merus stock opened at $44.84 on Friday. The firm has a fifty day moving average of $49.91 and a 200-day moving average of $51.81. Merus has a 52-week low of $22.27 and a 52-week high of $61.61. The firm has a market capitalization of $3.07 billion, a P/E ratio of -11.35 and a beta of 1.12.

Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The company had revenue of $11.77 million during the quarter, compared to analyst estimates of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. On average, research analysts expect that Merus will post -3.89 EPS for the current fiscal year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.